Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Misawa, S.
Right arrow Articles by Hattori, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Misawa, S.
Right arrow Articles by Hattori, T.
Neurology 2001;56:666-669
© 2001 American Academy of Neurology
Articles

Serum levels of tumor necrosis factor–{alpha} in chronic inflammatory demyelinating polyneuropathy

S. Misawa, MD;, S. Kuwabara, MD;, M. Mori, MD;, N. Kawaguchi, MD;, Y. Yoshiyama, MD; and T. Hattori, MD

From the Department of Neurology, Chiba University School of Medicine, Japan.

Address correspondence and reprint requests to Dr. S. Kuwabara, Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; e-mail: kwbr{at}mb.infoweb.ne.jp

BACKGROUND: Activated macrophages and T lymphocytes may play a role in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). Both cell types secrete tumor necrosis factor-{alpha} (TNF{alpha}), which has toxic effects on myelin and endothelial cells.

METHODS: The serum concentration of TNF{alpha} was measured by ELISA and compared with clinical and electrophysiological profiles in 20 patients with CIDP.

RESULTS: An increased serum level of TNF{alpha} was detected in 5 (25%) patients and was associated with subacute progression, severe neurologic disabilities, and symmetric weakness involving proximal as well as distal muscles. TNF{alpha} levels increased during the active phase in this subgroup of patients. The levels of TNF{alpha} correlated with the severity of demyelinating conduction abnormalities in the intermediate as well as distal nerve segments, suggesting demyelination diffusely distributed along the nerves.

CONCLUSION: Circulating TNF{alpha} increases during the active phase in a subgroup of CIDP patients and may play a role in the pathogenesis of demyelination and the breakdown of the blood–nerve barrier in CIDP.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L Sanvito, A Makowska, M Mahdi-Rogers, R D M Hadden, M Peakman, N Gregson, R Nemni, and R A C Hughes
Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy
J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 333 - 338.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Chio, D Cocito, E Bottacchi, C Buffa, M Leone, F Plano, R Mutani, A Calvo, and the PARCIDP
Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy
J. Neurol. Neurosurg. Psychiatry, December 1, 2007; 78(12): 1349 - 1353.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. Uceyler, J. P. Rogausch, K. V. Toyka, and C. Sommer
Differential expression of cytokines in painful and painless neuropathies
Neurology, July 3, 2007; 69(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Kuwabara, S Misawa, M Mori, N Tamura, M Kubota, and T Hattori
Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 66 - 70.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Bour-Jordan, H. L. Thompson, and J. A. Bluestone
Distinct Effector Mechanisms in the Development of Autoimmune Neuropathy versus Diabetes in Nonobese Diabetic Mice
J. Immunol., November 1, 2005; 175(9): 5649 - 5655.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. V. Toyka and R. Gold
The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents
Neurology, April 22, 2003; 60(90083): S2 - 7.
[Abstract] [Full Text]

Home page
 NeurologyHome page
B. C. Kieseier, M. C. Dalakas, and H.-P. Hartung
Immune mechanisms in chronic inflammatory demyelinating neuropathy
Neurology, December 24, 2002; 59(90126): S7 - 12.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D J Mahad, S J L Howell, and M N Woodroofe
Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy
J. Neurol. Neurosurg. Psychiatry, September 1, 2002; 73(3): 320 - 323.
[Abstract] [Full Text] [PDF]